Detailed medication instructions for the leukemia targeted drug giritinib (segatan)

Drug name: Gilteritinib

Drug categories: Targeted therapy drugs

Indications: For the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3-ITD or FLT3-TKD mutations.

Dosage form: Capsule

Dosage and usage:

1.Adult dosage:

Initial dose: 120 mg taken orally once daily.

Continue treatment: Monitor the patient's white blood cell count and bone marrow imaging during treatment. Dosage may be adjusted based on clinical response and severity of adverse reactions.

If a patient forgets to take giritinib, it should be taken as soon as possible before the next dose. If the next dose is very close to the time, the dose should be skipped.

2.Special groups:

Hepatic Impairment: No dose adjustment is required in patients with mild to moderate hepatic impairment (Child-Pugh A/B). In patients with severe hepatic impairment (Child-Pugh C), the dose needs to be reduced to 80 mg daily.

Impaired renal function: No dosage adjustments based on renal function are required.

3.Oral administration:

Oral capsules should be swallowed whole and should not be opened, chewed, or crushed.

Contraindications:

Contraindicated in persons allergic to giritinib or any component of this preparation.

Notes:

1.QT interval prolongation: The use of giritinib may lead to the prolongation of the QT interval. An electrocardiogram should be performed before treatment and monitored regularly.

2.Liver function monitoring: Liver function should be monitored during treatment, including transaminases, total bilirubin and direct bilirubin. If liver function abnormalities occur, dose reduction or treatment suspension should be considered.

3.Myelosuppression: Blood cell counts should be monitored during treatment. If leukopenia, anemia or thrombocytopenia occurs, corresponding treatment measures should be taken as needed.

4.Pregnancy and lactation: Giritinib may cause fetal harm and should be avoided during pregnancy. Female patients should avoid becoming pregnant during treatment and for at least 6 months after treatment, and should use effective contraceptive measures during this period.

Adverse reactions:

1.Digestive tract discomfort: Including nausea, vomiting, diarrhea, etc.

2.Fatigue and weakness: Fatigue and weakness may occur, affecting daily activities.

3.Abnormal liver function: It may lead to abnormal liver function such as elevated transaminases.

4.Electrocardiogram abnormalities: May cause QT prolongation of the QT interval and other electrocardiogram abnormalities.

5.Myelosuppression: Including leukopenia, anemia and thrombocytopenia.

6.Other adverse reactions: Headache, fever, rash, joint pain, etc.

Drug interactions:

Giritinib may affect the metabolism of other drugs by inhibitingCYP3A4. Caution should be exercised when coadministering CYP3A4 substrates (such as clozapine, felodipine, etc.).

Storage:

Should be stored in a sealed container, away from moisture and light, at room temperature (15-30 degrees Celsius).

Availability and Price:

Although giritinib has been launched in the domestic market, unfortunately, it has not yet been included in the scope of medical insurance, so the domestic price remains high, as high as more than 20,000 yuan. For more specific pricing, please check with your local hospital pharmacy. In comparison, foreign generic drugs appear to be more user-friendly. In particular, the price of generic drugs from Laos is only about two to three thousand yuan, which is far lower than the domestic market price. It is worth mentioning that the ingredients of these generic drugs are almost the same as those of domestic original drugs.

The above is the detailed medication instructions for giritinib. Patients should read the drug instructions carefully before using the drug and use the drug correctly under the guidance of a doctor. If you have any questions or adverse reactions, you should consult your doctor promptly.